Mayo clinic starting Cancer RCT using grossly inadequate 2,000 IU of vitamin D

Vitamin D in the cancer patient.

Curr Opin Support Palliat Care. 2013 Sep;7(3):272-7. doi: 10.1097/SPC.0b013e3283640f74.

Kennel KA, Drake MT.

Division of Endocrinology, Department of Medicine, Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PURPOSE OF REVIEW: To briefly review recent work within the vitamin D and cancer field, whereas also providing context relating how these findings may impact clinical care and future research efforts.

RECENT FINDINGS: Vitamin D has now been convincingly shown both in vitro and in preclinical animal models to alter the differentiation, proliferation, and apoptosis of cancer cells. Whether vitamin D prevents cancer in humans or limits cancer progression, however, remain open questions. Epidemiologic and observational data relating circulating 25(OH)D levels and cancer risk suggest an inverse relationship for most cancers including breast, colorectal, leukemia and lymphoma, and prostate, although for each malignancy there also exist studies that have failed to demonstrate such an inverse relationship. Likewise, a more recent report failed to confirm a previously reported association of increased pancreatic cancer risk in patients with higher 25(OH)D levels. A large prospective study in which patients aged at least 50 years receive 2000 IU vitamin D3 daily for 5 years, with cancer as a primary endpoint, has recently been launched.

SUMMARY: Although much effort has attempted to delineate a causal relationship between vitamin D and a wide array of human cancers, we await large-scale randomized controlled trial data for definitive answers.

PMID: 23912386


Comment by VitaminDWiki

  • Far too little vitamin D for far too short of time (12 weeks). Very unlikely to be successful

  • 10,000 IU daily for 24 weeks would be far better

image

See also VitaminDWiki

image


This is apparently the MAYO Clinical Trial referred to

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Random Controlled Trial, Weekly Injection for 12 weeks, 965 patients

Types of Cancer in the RCT

Adult Nasal Type Extranodal NK/T-cell Lymphoma

Anaplastic Large Cell Lymphoma

Angioimmunoblastic T-cell Lymphoma

Contiguous Stage II Adult Diffuse Large Cell Lymphoma

Hepatosplenic T-cell Lymphoma

Male Breast Cancer

Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

Peripheral T-cell Lymphoma

Stage 0 Chronic Lymphocytic Leukemia

Stage I Adult Diffuse Large Cell Lymphoma

Stage I Chronic Lymphocytic Leukemia

Stage I Colon Cancer

Stage I Cutaneous T-cell Non-Hodgkin Lymphoma

Stage I Rectal Cancer

Stage I Small Lymphocytic Lymphoma

Stage IA Breast Cancer

Stage IB Breast Cancer

Stage II Breast Cancer

Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

Stage IIA Colon Cancer

Stage IIA Rectal Cancer

Stage IIB Colon Cancer

Stage IIB Rectal Cancer

Stage IIC Colon Cancer

Stage IIC Rectal Cancer

Stage III Adult Diffuse Large Cell Lymphoma

Stage III Cutaneous T-cell Non-Hodgkin Lymphoma

Stage IIIA Breast Cancer

Stage IIIA Colon Cancer

Stage IIIA Rectal Cancer

Stage IIIB Breast Cancer

Stage IIIB Colon Cancer

Stage IIIB Rectal Cancer

Stage IIIC Breast Cancer

Stage IIIC Colon Cancer

Stage IIIC Rectal Cancer

Stage IV Adult Diffuse Large Cell Lymphoma

Stage IV Breast Cancer

Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

Stage IVA Colon Cancer

Stage IVA Rectal Cancer

Stage IVB Colon Cancer

Stage IVB Rectal Cancer